MEESSI-acute heart failure risk score validated

MEESSI-acute heart failure risk score validated

(HealthDay)—The Multiple Estimation of risk based on the Emergency department Spanish Score In patients with Acute Heart Failure (MEESSI-AHF) can accurately predict 30-day mortality in patients with AHF, according to a study published online Jan. 29 in the Annals of Internal Medicine.

Desiree Wussler, M.D., from the University Hospital Basel in Switzerland, and colleagues conducted a prospective cohort study to externally validate the MEESSI-AHF score in 1,572 patients with AHF in a country other than Spain. Of the patients with adjudicated AHF, 1,247 had complete data that allowed calculation of the MEESSI-AHF score.

The researchers found that 8.2 percent of the patients with complete data died within 30 days. Thirty-day mortality was predicted by the score with excellent discrimination (c-statistic, 0.80). Across six predefined risk groups, assessment of cumulative mortality showed a steep gradient in (from zero patients in the lowest-risk group to 35 [28.5 percent] in the highest-risk group). In the high-risk groups, risk was overestimated, resulting in a Hosmer-Lemeshow P value of 0.022. The model showed good concordance between predicted risks and observed outcomes after adjustment of the intercept (P = 0.23). The findings were confirmed in sensitivity analyses.

"We believe that this risk score is a highly promising tool for more widespread risk stratification of with AHF in the ," the authors write. "However, recalibration may be needed when the score is introduced to a new population."

Several authors disclosed financial ties to the pharmaceutical industry.

More information: Abstract/Full Text (subscription or payment may be required)

Journal information: Annals of Internal Medicine

Copyright © 2019 HealthDay. All rights reserved.

Citation: MEESSI-acute heart failure risk score validated (2019, January 29) retrieved 23 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Canadian syncope risk score IDs ED monitoring time postsyncope


Feedback to editors